Pep 2-8是一种由13个氨基酸组成的线性肽，可抑制PCSK9活性（KD=0.7μM），并抑制LDL受体及EGF(A)结构域与PCSK9的结合，IC50值分别为0.8μM和0.4μM。
Cas No.:1541011-97-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Pep 2-8, a linear peptide consisting of 13 amino acids, inhibits PCSK9 with a KD value of 0.7μM and suppresses the binding of LDL receptors and the EGF(A) domain to PCSK9, with IC50 values of 0.8 and 0.4μM, respectively [1]. Pep 2-8 neutralizes the activity of PCSK9, prevents the degradation of LDL receptors and restore the function of LDL receptors in cells[2]. Pep 2-8 has been widely used as a model compound to develop a series of derivatives for regulating the level of LDLR protein in cells [3].
In vitro, Pep 2-8 treatment for 24h (10µM) in the presence of lipopolysaccharide (20ng/mL;24h) significantly decreased phosphorylation of mTOR in vascular smooth muscle cells (VSMCs) and decreased apoptosis[4]. Pep 2-8 (10μM) pretreatment of VSMCs from obese insulin-resistant Zucker rats for 30 minutes can inhibit the expression of pERK-1/2 induced by a high glucose environment, and block the activation of the MAPK/ERK-1/2 pathway[5].
In vivo, Pep 2-8 treatment via subcutaneous injection (10µg/kg) once every two weeks for 10 weeks significantly inhibited the downregulation of NOX4, MAPK subunits, and NF-κB expression caused by PCSK9 in the aorta of mice, as well as the secretion of pro-inflammatory cytokines, preventing vascular aging[6]. A single intravenous injection of Pep 2-8 (10μg/kg) for 120 minutes reduced the myocardial infarction area in rats with ischemia/reperfusion injury, improved the mitochondrial function of the heart, and decreased the expression of apoptosis-related proteins[7]. Intravenous injection of Pep 2-8 (10µg per mouse/day) for one week improved the contractile function of the hearts of mice with left coronary artery (LCA) occlusion and inhibited the autophagic activity in ischemic hearts[8].
References:
[1] Zhang Y, Eigenbrot C, Zhou L, et al. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor[J]. Journal of Biological Chemistry, 2014, 289(2): 942-955.
[2] Lammi C, Sgrignani J, Arnoldi A, et al. Biological characterization of computationally designed analogs of peptide TVFTSWEEYLDWV (Pep2-8) with increased PCSK9 antagonistic activity[J]. Scientific reports, 2019, 9(1): 2343.
[3] Tombling B J, Lammi C, Bollati C, et al. Increased valency improves inhibitory activity of peptides targeting proprotein convertase subtilisin/kexin type 9 (PCSK9)[J]. ChemBioChem, 2021, 22(12): 2154-2160.
[4] Ding Z, Liu S, Wang X, et al. Cross-talk between PCSK9 and damaged mtDNA in vascular smooth muscle cells: role in apoptosis[J]. Antioxidants & redox signaling, 2016, 25(18): 997-1008.
[5] Barale C, Tempesta G, Melchionda E, et al. PCSK9 Expression in Vascular Smooth Muscle Cells: Role of Insulin Resistance and High Glucose[J]. International Journal of Molecular Sciences, 2025, 26(3): 1003.
[6] Liu S, Wu J, Stolarz A, et al. PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging[J]. Theranostics, 2023, 13(9): 2914.
[7] Palee S, McSweeney C M, Maneechote C, et al. PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid‐lowering effects[J]. Journal of cellular and molecular medicine, 2019, 23(11): 7310-7319.
[8] Ding Z, Wang X, Liu S, et al. PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy[J]. Cardiovascular Research, 2018, 114(13): 1738-1751.
Pep 2-8是一种由13个氨基酸组成的线性肽，可抑制PCSK9活性（KD=0.7μM），并抑制LDL受体及EGF(A)结构域与PCSK9的结合，IC50值分别为0.8μM和0.4μM[1]。Pep 2-8通过中和PCSK9活性，阻止LDL受体降解并恢复细胞中LDL受体功能[2]。Pep 2-8已被广泛作为模型化合物用于开发调控细胞LDLR蛋白水平的一系列衍生物[3]。
在体外，在脂多糖（20ng/mL；24小时）存在下，10µM的Pep 2-8处理24小时可显著降低血管平滑肌细胞（VSMCs）中mTOR磷酸化水平并减少细胞凋亡[4]。10μM的Pep 2-8预处理来自肥胖胰岛素抵抗Zucker大鼠的VSMCs 30分钟，能抑制高糖环境诱导的pERK-1/2表达，并阻断MAPK/ERK-1/2通路激活[5]。
在体内，小鼠每两周皮下注射Pep 2-8（10µg/kg；持续10周）可显著抑制主动脉中PCSK9引起NOX4、MAPK亚基和NF-κB表达的下调，减少促炎细胞因子分泌，延缓血管老化[6]。大鼠单次静脉注射10μg/kg剂量的Pep 2-8（120分钟）能减少缺血/再灌注损伤后的心肌梗死面积，改善心脏线粒体功能并降低凋亡相关蛋白表达[7]。左冠状动脉结扎小鼠每日静脉注射10µg的Pep 2-8（持续一周）可改善心脏收缩功能，并抑制缺血心脏的自噬活性[8]。
| Cell experiment [1]: | |
Cell lines | HepG2 cells |
Preparation Method | HepG2 cells were seeded at a density of 3×104 cells per well in a 96-well plate. After 24 hours, the culture medium was replaced with DMEM medium containing 10% lipoprotein-deficient serum. Different concentrations of Pep 2-8(1.5, 3.0, 6.0, 12.5, 25, 50, 100, and 200μM) were pre-incubated with 15μg/ml PCSK9 (dissolved in 0.5% DMSO) for 30 minutes, and then added to the cells. After 1.5 hours, 10μg/ml BODIPY-LDL was added and incubated for 3.5 hours. The cells were washed three times with PBS and the fluorescence was measured on a microplate reader. |
Reaction Conditions | 1.5, 3.0, 6.0, 12.5, 25, 50, 100, and 200μM; 4h |
Applications | Pep 2-8 treatment significantly restored LDL uptake in HepG2 cells. |
| Animal experiment [2]: | |
Animal models | Male C57BL/6 mice |
Preparation Method | Male C57BL/6 mice were raised under standard conditions. Before reaching 24 months of age, they were subcutaneously injected with the Pep 2-8 (10µg/kg dissolved in 100µL normal saline) or 100µL normal saline every 2 weeks for a total of 10 weeks (10 mice in each group). After injecting Pep 2-8, the mice were monitored daily. At 24-month endpoint, after euthanizing the mice by CO2 asphyxiation, the aorta samples were dissected for further molecular and immunohistochemical analyses. |
Dosage form | 10µg/kg every 2 weeks for 10 weeks; s.c. |
Applications | Pep 2-8 treatment downregulated the expressions of the aging markers pro-IL-1β, NF-κB and p22phox in the aortic arch of mice. |
References: | |
| Cas No. | 1541011-97-5 | SDF | |
| 别名 | TVFTSWEEYLDWV-NH2 | ||
| 分子式 | C83H110N16O24 | 分子量 | 1715.88 |
| 溶解度 | Soluble 2mg/mL in PBS (pH 7.4) | 储存条件 | store at -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 582.8 μL | 2.914 mL | 5.8279 mL |
| 5 mM | 116.6 μL | 582.8 μL | 1.1656 mL |
| 10 mM | 58.3 μL | 291.4 μL | 582.8 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet